BioLineRx (BLRX) Tops Q3 EPS by 8c Nov 24, 2025 07:37AM
BioLineRx (BLRX) Reports In-Line Q2 EPS Aug 14, 2025 07:14AM
H.C. Wainwright Reiterates Buy Rating on BioLineRx (BLRX) Jun 17, 2025 06:42AM
Jones Trading Upgrades BioLineRx (BLRX) to Buy May 30, 2025 08:59AM
BioLineRx (BLRX) to Present New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide May 30, 2025 07:00AM


May 28, 2025 08:59AM Jones Trading Reiterates Hold Rating on BioLineRx (BLRX)
May 28, 2025 06:57AM H.C. Wainwright Reiterates Buy Rating on BioLineRx (BLRX)
May 27, 2025 04:22PM BioLineRx (BLRX) Tops Q1 EPS by 10c
Apr 1, 2025 04:31PM Jones Trading Downgrades BioLineRx (BLRX) to Hold
Apr 1, 2025 06:47AM BioLineRx (BLRX) PT Raised to $26 at H.C. Wainwright
Jan 21, 2025 07:01AM BioLineRx (BLRX) Issues Letter to Shareholders
Jan 6, 2025 08:58AM BioLineRx (BLRX) Announces 50M Share Offering at $0.20/sh
Nov 26, 2024 06:59AM BioLineRx (BLRX) PT Lowered to $9 at H.C. Wainwright
Nov 25, 2024 07:05AM BioLineRx (BLRX) Tops Q3 EPS by 4c
Nov 21, 2024 06:31AM BioLineRx (BLRX) and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA
Oct 16, 2024 07:02AM BioLineRx (BLRX) Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
Sep 3, 2024 04:10PM Jones Trading Starts BioLineRx (BLRX) at Buy
Aug 15, 2024 07:01AM BioLineRx (BLRX) Tops Q2 EPS by 14c